Sign In
Buy PRN
$247.56
+1.45 (+0.588%)
At Close: Jun 03, 2026
Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference
08:30pm, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference
08:30pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical Annual and Special Meeting of Shareholders Voting Results
09:43pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special
Profound Medical Clarifies Recent Insider Buying
08:30pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its
TULSA-PRO® Was Front and Center at AUA2022
09:25pm, Tuesday, 17'th May 2022 GlobeNewswire Inc.
Activities Highlighting Profound’s Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern’s Dr. Kenneth A. Goldberg During Meeting’s Plenary Session Activit
Profound Medical Announces First Quarter 2022 Financial Results
08:05pm, Monday, 09'th May 2022 GlobeNewswire Inc.
TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cus
Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
08:30pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow
08:30pm, Monday, 18'th Apr 2022 GlobeNewswire Inc.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results
09:03pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
Profound Medical to Participate in March Investor Conferences
01:00pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
Should You Invest in the Invesco DWA Industrials Momentum ETF (PRN)?
11:20am, Thursday, 17'th Feb 2022 Zacks Investment Research
Sector ETF report for PRN
Should You Invest in the Invesco DWA Industrials Momentum ETF (PRN)?
07:44am, Thursday, 17'th Feb 2022
Sector ETF report for PRN
Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow
09:30pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
09:30pm, Tuesday, 08'th Feb 2022 GlobeNewswire Inc.
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
12:33pm, Tuesday, 18'th Jan 2022 GlobeNewswire Inc.
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
